It is predicted that rapid increase in DM prevalence will result in a parallel increase in diabetic microvascular complications including diabetic retinopathy and nephropathy [26], reinforcing the need for stringent safety evaluation of intravitreal anti-VEGF therapies. The gene discussed is VEGFA; the disease is diabetes mellitus.